Eculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety – a single-center study
Objective To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.Method Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory...
Saved in:
Main Authors: | Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2025.2450575 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A 2-decade survival from a double hemolytic disease: A case of paroxysmal nocturnal hemoglobinuria with hemoglobinopathy
by: Aria Namiq Chaqmachi, et al.
Published: (2024-12-01) -
Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuria
by: Marek Ussowicz, et al.
Published: (2025-01-01) -
A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report
by: Sabine Hermann, et al.
Published: (2025-02-01) -
A method for selecting P antigen-negative red cell units for patients with paroxysmal cold hemoglobinuria
by: Geethika Sajeewani Manchanayake
Published: (2024-01-01) -
Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
by: Ethan Burns, et al.
Published: (2019-01-01)